Prognostic is not predictive: from statistical association to actionable biomarkers in urologic oncology
Author:
Open Access
- 1 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Urological Science
- Vol. 37 (4) , 193-194
Abstract
Was not provided for this article.Keywords
This publication has 10 references indexed in Scilit:
- Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugatesCancer Treatment Reviews, 2026
- A decision-oriented framework for genomic testing across the prostate cancer continuumCancer Genetics, 2026
- Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinationsThe Oncologist, 2026
- Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical PerspectiveEuropean Urology Oncology, 2026
- NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinomaClinical and Experimental Medicine, 2026
- Towards biomarker-driven therapies for urothelial carcinomaNature Reviews Clinical Oncology, 2025
- Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsJournal of Clinical Oncology, 2025
- Validation of neutrophil-to-lymphocyte ratio for prognosis and treatment selection in muscle-invasive bladder cancer: A single-institutional longitudinal studyUrological Science, 2025
- Tumor suppressor MiRNAs in bladder tumors: From preclinical research to therapeutic applicationsUrological Science, 2025
- Prognostic value of systemic immune-inflammation index in patients with locally advanced renal cell carcinomaUrological Science, 2024